STERIALS

A biotechnology company focused on developing new drugs to treat and cure patients with solid tumors. For many patients who do not respond to conventional immunotherapy or experience relapse after an initial response, the company is developing next-generation TIL therapy using a differentiated approach to tumor-infiltrating lymphocytes (TIL), and is conducting clinical trials for breast cancer, colon cancer, and uveal melanoma. Based in Delaware.